Bioinformatics analysis and consistency verification of a novel tuberculosis vaccine candidate HP13138PB
BackgroundWith the increasing incidence of tuberculosis (TB) and the shortcomings of existing TB vaccines to prevent TB in adults, new TB vaccines need to be developed to address the complex TB epidemic.MethodThe dominant epitopes were screened from antigens to construct a novel epitope vaccine term...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1102578/full |
| _version_ | 1811170146620801024 |
|---|---|
| author | Peng Cheng Peng Cheng Fan Jiang Guiyuan Wang Guiyuan Wang Jie Wang Yong Xue Liang Wang Wenping Gong |
| author_facet | Peng Cheng Peng Cheng Fan Jiang Guiyuan Wang Guiyuan Wang Jie Wang Yong Xue Liang Wang Wenping Gong |
| author_sort | Peng Cheng |
| collection | DOAJ |
| description | BackgroundWith the increasing incidence of tuberculosis (TB) and the shortcomings of existing TB vaccines to prevent TB in adults, new TB vaccines need to be developed to address the complex TB epidemic.MethodThe dominant epitopes were screened from antigens to construct a novel epitope vaccine termed HP13138PB. The immune properties, structure, and function of HP13138PB were predicted and analyzed with bioinformatics and immunoinformatics. Then, the immune responses induced by the HP13138PB were confirmed by enzyme-linked immunospot assay (ELISPOT) and Th1/Th2/Th17 multi-cytokine detection kit.ResultThe HP13138PB vaccine consisted of 13 helper T lymphocytes (HTL) epitopes, 13 cytotoxic T lymphocytes (CTL) epitopes, and 8 B-cell epitopes. It was found that the antigenicity, immunogenicity, and solubility index of the HP13138PB vaccine were 0.87, 2.79, and 0.55, respectively. The secondary structure prediction indicated that the HP13138PB vaccine had 31% of α-helix, 11% of β-strand, and 56% of coil. The tertiary structure analysis suggested that the Z-score and the Favored region of the HP13138PB vaccine were -4.47 88.22%, respectively. Furthermore, the binding energies of the HP13138PB to toll-like receptor 2 (TLR2) was -1224.7 kcal/mol. The immunoinformatics and real-world experiments showed that the HP13138PB vaccine could induce an innate and adaptive immune response characterized by significantly higher levels of cytokines such as interferon-gamma (IFN-γ), tumor necrosis factor-α (TNF-α), interleukin-4 (IL-4), and IL-10.ConclusionThe HP13138PB is a potential vaccine candidate to prevent TB, and this study preliminarily evaluated the ability of the HP13138PB to generate an immune response, providing a precursor target for developing TB vaccines. |
| first_indexed | 2024-04-10T16:52:21Z |
| format | Article |
| id | doaj.art-b7e33ac0791d45dd832f1181e3a8e70a |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-10T16:52:21Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-b7e33ac0791d45dd832f1181e3a8e70a2023-02-07T14:02:18ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-01-011410.3389/fimmu.2023.11025781102578Bioinformatics analysis and consistency verification of a novel tuberculosis vaccine candidate HP13138PBPeng Cheng0Peng Cheng1Fan Jiang2Guiyuan Wang3Guiyuan Wang4Jie Wang5Yong Xue6Liang Wang7Wenping Gong8Tuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The Eighth Medical Center of PLA General Hospital, Beijing, ChinaDepartment of Geriatrics, The Eighth Medical Center of PLA General Hospital, Beijing, ChinaThe Second Brigade of Cadet, Basic Medical School, Air Force Military Medical University, Xi’an, Shaanxi, ChinaTuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The Eighth Medical Center of PLA General Hospital, Beijing, ChinaHebei North University, Zhangjiakou, Hebei, ChinaTuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The Eighth Medical Center of PLA General Hospital, Beijing, ChinaTuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The Eighth Medical Center of PLA General Hospital, Beijing, ChinaDepartment of Geriatrics, The Eighth Medical Center of PLA General Hospital, Beijing, ChinaTuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The Eighth Medical Center of PLA General Hospital, Beijing, ChinaBackgroundWith the increasing incidence of tuberculosis (TB) and the shortcomings of existing TB vaccines to prevent TB in adults, new TB vaccines need to be developed to address the complex TB epidemic.MethodThe dominant epitopes were screened from antigens to construct a novel epitope vaccine termed HP13138PB. The immune properties, structure, and function of HP13138PB were predicted and analyzed with bioinformatics and immunoinformatics. Then, the immune responses induced by the HP13138PB were confirmed by enzyme-linked immunospot assay (ELISPOT) and Th1/Th2/Th17 multi-cytokine detection kit.ResultThe HP13138PB vaccine consisted of 13 helper T lymphocytes (HTL) epitopes, 13 cytotoxic T lymphocytes (CTL) epitopes, and 8 B-cell epitopes. It was found that the antigenicity, immunogenicity, and solubility index of the HP13138PB vaccine were 0.87, 2.79, and 0.55, respectively. The secondary structure prediction indicated that the HP13138PB vaccine had 31% of α-helix, 11% of β-strand, and 56% of coil. The tertiary structure analysis suggested that the Z-score and the Favored region of the HP13138PB vaccine were -4.47 88.22%, respectively. Furthermore, the binding energies of the HP13138PB to toll-like receptor 2 (TLR2) was -1224.7 kcal/mol. The immunoinformatics and real-world experiments showed that the HP13138PB vaccine could induce an innate and adaptive immune response characterized by significantly higher levels of cytokines such as interferon-gamma (IFN-γ), tumor necrosis factor-α (TNF-α), interleukin-4 (IL-4), and IL-10.ConclusionThe HP13138PB is a potential vaccine candidate to prevent TB, and this study preliminarily evaluated the ability of the HP13138PB to generate an immune response, providing a precursor target for developing TB vaccines.https://www.frontiersin.org/articles/10.3389/fimmu.2023.1102578/fulltuberculosisepitope vaccinesimmunoinformaticsimmune responsesbioinformatics |
| spellingShingle | Peng Cheng Peng Cheng Fan Jiang Guiyuan Wang Guiyuan Wang Jie Wang Yong Xue Liang Wang Wenping Gong Bioinformatics analysis and consistency verification of a novel tuberculosis vaccine candidate HP13138PB Frontiers in Immunology tuberculosis epitope vaccines immunoinformatics immune responses bioinformatics |
| title | Bioinformatics analysis and consistency verification of a novel tuberculosis vaccine candidate HP13138PB |
| title_full | Bioinformatics analysis and consistency verification of a novel tuberculosis vaccine candidate HP13138PB |
| title_fullStr | Bioinformatics analysis and consistency verification of a novel tuberculosis vaccine candidate HP13138PB |
| title_full_unstemmed | Bioinformatics analysis and consistency verification of a novel tuberculosis vaccine candidate HP13138PB |
| title_short | Bioinformatics analysis and consistency verification of a novel tuberculosis vaccine candidate HP13138PB |
| title_sort | bioinformatics analysis and consistency verification of a novel tuberculosis vaccine candidate hp13138pb |
| topic | tuberculosis epitope vaccines immunoinformatics immune responses bioinformatics |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1102578/full |
| work_keys_str_mv | AT pengcheng bioinformaticsanalysisandconsistencyverificationofanoveltuberculosisvaccinecandidatehp13138pb AT pengcheng bioinformaticsanalysisandconsistencyverificationofanoveltuberculosisvaccinecandidatehp13138pb AT fanjiang bioinformaticsanalysisandconsistencyverificationofanoveltuberculosisvaccinecandidatehp13138pb AT guiyuanwang bioinformaticsanalysisandconsistencyverificationofanoveltuberculosisvaccinecandidatehp13138pb AT guiyuanwang bioinformaticsanalysisandconsistencyverificationofanoveltuberculosisvaccinecandidatehp13138pb AT jiewang bioinformaticsanalysisandconsistencyverificationofanoveltuberculosisvaccinecandidatehp13138pb AT yongxue bioinformaticsanalysisandconsistencyverificationofanoveltuberculosisvaccinecandidatehp13138pb AT liangwang bioinformaticsanalysisandconsistencyverificationofanoveltuberculosisvaccinecandidatehp13138pb AT wenpinggong bioinformaticsanalysisandconsistencyverificationofanoveltuberculosisvaccinecandidatehp13138pb |